Form4insider filings, from the source

SEC Form 4 · accession 0001209191-19-016941

Denali Therapeutics Inc. · DNLI

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Carole Ho
Officer — Chief Medical Officer
Period of report
Mar 1, 2019
Accepted (ET)
Mar 5, 2019 · 6:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001714899

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockMar 1, 2019M5,775$5.28A5,775D
Common StockF5Mar 1, 2019S3,824$22.17D1,951D
Common StockF6Mar 1, 2019S1,951$22.92D0D
Common StockMar 4, 2019M5,863$5.28A5,863D
Common StockF7Mar 4, 2019S4,263$21.87D1,600D
Common StockF8Mar 4, 2019S1,600$22.84D0D
Common StockMar 5, 2019M5,862$5.28A5,862D
Common StockF9Mar 5, 2019S5,862$21.96D0D
Common StockF1holding———46,875D
Common StockF2holding———25,000ISee footnote
Common StockF3holding———142,615ISee footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (right to buy)F10$5.28Mar 1, 2019M5,775D—Mar 7, 2027Common Stock5,775123,855D
Stock Option (right to buy)F10$5.28Mar 4, 2019M5,863D—Mar 7, 2027Common Stock5,863117,992D
Stock Option (right to buy)F10$5.28Mar 5, 2019M5,862D—Mar 7, 2027Common Stock5,862112,130D

Explanation of responses